Tyrosine kinase inhibitorFDA-approvedFirst-line
Imatinib
How it works
Blocks the BCR-ABL tyrosine kinase enzyme, which is overactive in CML cells, and also inhibits other tyrosine kinases involved in cancer growth.
Cancer types
Leukemia— BCR-ABL-positive
Efficacy
In clinical trials, around 90% of BCR-ABL-positive patients achieved a major cytogenetic response, with a median progression-free survival of approximately 8 years.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Imatinib Triggers Early Changes in Cancer Cells | Leukemia | lab-study | — | Source → |
| Pregnancy Risks with Leukemia Medications | Leukemia | observational | — | Source → |
| Ponatinib Improves Quality of Life for Leukemia Patients | Leukemia | phase-3 | — | Source → |
| Combining treatments for lung cancer and blood disorder | Lung Cancer | observational | — | Source → |
| Ponatinib vs Imatinib for Leukemia Treatment: Cost Comparison | Leukemia | phase-3 | Ponatinib offered an approximate gain of 3 months of life and 6 months of quality-adjusted life. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.